{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:40:52Z","timestamp":1791726052542,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Delhi State Tuberculosis Cell, New Delhi, India"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00228-024-03754-x","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T09:07:19Z","timestamp":1726650439000},"page":"1945-1958","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacokinetics-pharmacodynamics of first-line antitubercular drugs: a comparative study in tuberculosis patients with and without concomitant diabetes mellitus"],"prefix":"10.1007","volume":"80","author":[{"given":"Sourav","family":"Mondal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish Gulab","family":"Meshram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thirumurthy","family":"Velpandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"issue":"1","key":"3754_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s44197-021-00025-1","volume":"12","author":"S Fazaludeen Koya","year":"2022","unstructured":"Fazaludeen Koya S, Lordson J et al (2022) Tuberculosis and diabetes in India: stakeholder perspectives on health system challenges and opportunities for integrated care. J Epidemiol Glob Health 12(1):104\u2013112","journal-title":"J Epidemiol Glob Health"},{"issue":"1","key":"3754_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/tropicalmed6010008","volume":"6","author":"R van Crevel","year":"2021","unstructured":"van Crevel R, Critchley JA (2021) The interaction of diabetes and tuberculosis: translating research to policy and practice. Trop Med Infect Dis 6(1):8","journal-title":"Trop Med Infect Dis"},{"key":"3754_CR3","unstructured":"Guidelines for programmatic management of drug resistant tuberculosis in India 2021. Downloaded from https:\/\/tbcindia.gov.in\/showfile.php?lid=3590. Last accessed on 3 Aug 2023"},{"issue":"8","key":"3754_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/BF03261926","volume":"51","author":"M Dostalek","year":"2012","unstructured":"Dostalek M, Akhlaghi F, Puzanovova M (2012) Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet 51(8):481\u201399","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"3754_CR5","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1128\/AAC.01345-13","volume":"57","author":"A Babalik","year":"2013","unstructured":"Babalik A, Ulus IH, Bakirci N et al (2013) Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus. Antimicrob Agents Chemother 57(11):5740\u20132","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"3754_CR6","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1086\/507543","volume":"43","author":"HMJ Nijland","year":"2006","unstructured":"Nijland HMJ, Ruslami R, Stalenhoef JE et al (2006) Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 43(7):848\u201354","journal-title":"Clin Infect Dis"},{"issue":"11","key":"3754_CR7","doi-asserted-by":"publisher","first-page":"e01383","DOI":"10.1128\/AAC.01383-18","volume":"62","author":"O Alfarisi","year":"2018","unstructured":"Alfarisi O, Mave V, Gaikwad S et al (2018) Effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment. Antimicrob Agents Chemother 62(11):e01383-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"3754_CR8","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1093\/jac\/dkz368","volume":"74","author":"CM Mtabho","year":"2019","unstructured":"Mtabho CM, Semvua HH, van den Boogaard J et al (2019) Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. J Antimicrob Chemother 74(12):3537\u201345","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"3754_CR9","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1128\/AAC.00447-09","volume":"54","author":"R Ruslami","year":"2010","unstructured":"Ruslami R, Nijland HM, Adhiarta IG et al (2010) Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother 54(3):1068\u201374","journal-title":"Antimicrob Agents Chemother"},{"key":"3754_CR10","doi-asserted-by":"crossref","unstructured":"Ramachandran G, Chandrasekaran P, Gaikwad S, et al (2020) Cohort for Tuberculosis Research by the Indo-US Partnership (CTRIUMPh) Team. Subtherapeutic rifampicin concentration is associated with unfavorable tuberculosis treatment outcomes. Clin Infect Dis 70(7):1463-1470","DOI":"10.1093\/cid\/ciz380"},{"issue":"2\u20133","key":"3754_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4103\/ijmr.IJMR_1835_19","volume":"157","author":"G Ramachandran","year":"2023","unstructured":"Ramachandran G, Hemanth Kumar AK, Kannan T et al (2023) Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: a preliminary study. Indian J Med Res 157(2\u20133):211\u2013215","journal-title":"Indian J Med Res"},{"issue":"9","key":"3754_CR12","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.5588\/ijtld.16.0048","volume":"20","author":"AK Hemanth Kumar","year":"2016","unstructured":"Hemanth Kumar AK, Kannan T, Chandrasekaran V et al (2016) Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India. Int J Tuberc Lung Dis 20(9):1236\u201341","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"3754_CR13","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/apm.12590","volume":"124","author":"JB Prahl","year":"2016","unstructured":"Prahl JB, Lundqvist M, Bahl JM et al (2016) Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography\/tandem mass spectrometry. APMIS 124(11):1004\u20131015","journal-title":"APMIS"},{"key":"3754_CR14","unstructured":"U.S. Food and Drug Administration (2018) Bioanalytical method validation guidance for industry. [Internet]. Rockville (MD): U.S. Food and Drug Administration [cited 2024 Aug 8]. Available from: https:\/\/www.fda.gov\/media\/70858\/download. Accessed 8 Aug 2024"},{"issue":"1","key":"3754_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/bcpt.13482","volume":"128","author":"K Ram","year":"2021","unstructured":"Ram K, Sheikh S, Bhati RK et al (2021) Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome. Basic Clin Pharmacol Toxicol 128(1):128\u2013140","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3754_CR16","unstructured":"WHO (2021) Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine). [Internet]. Geneva: World Health Organization [cited 2024 Aug 8]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240017283. Accessed 8 Aug 2024"},{"issue":"15","key":"3754_CR17","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","volume":"62","author":"CA Peloquin","year":"2002","unstructured":"Peloquin CA (2002) Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62(15):2169\u201383","journal-title":"Drugs"},{"key":"3754_CR18","unstructured":"The use of the WHO-UMC system for standardized case causality assessment. [Internet]. Uppsala: World Health Organization (WHO)-Uppsala Monitoring Centre. 2018 [cited 2024 Aug 8]. Available from: https:\/\/who-umc.org\/media\/164200\/who-umc-causality-assessment_new-logo.pdf. Accessed 8 Aug 2024"},{"key":"3754_CR19","unstructured":"Gumbo T (2018) Chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy. In: Brunton L, Hilal-Dandan R, Knollmann BC (eds) Goodman and Gilman\u2019s The pharmacological basis of therapeutics (13th ed.) McGraw-Hil, New York, pp 1067-74"},{"issue":"4","key":"3754_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.arcmed.2011.06.007","volume":"42","author":"S Semiz","year":"2011","unstructured":"Semiz S, Dujic T, Ostanek B et al (2011) Association of NAT2 polymorphisms with type 2 diabetes in a population from Bosnia and Herzegovina. Arch Med Res 42(4):311\u201317","journal-title":"Arch Med Res"},{"key":"3754_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2490-5-12","volume":"5","author":"DS Srivastava","year":"2005","unstructured":"Srivastava DS, Mittal RD (2005) Genetic polymorphism of the N-acetyltransferase 2 gene, and susceptibility to prostate cancer: a pilot study in north Indian population. BMC Urol 5:12","journal-title":"BMC Urol"},{"issue":"1","key":"3754_CR22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4103\/ijmr.IJMR_2013_15","volume":"145","author":"AK Hemanth Kumar","year":"2017","unstructured":"Hemanth Kumar AK, Ramesh K, Kannan T et al (2017) N-acetyltransferase gene polymorphisms and plasma isoniazid concentrations in patients with tuberculosis. Indian J Med Res 145(1):118\u2013123","journal-title":"Indian J Med Res"},{"key":"3754_CR23","doi-asserted-by":"crossref","unstructured":"Wang P, Pradhan K, Zhong et al (2016) Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B 6(5):384-392","DOI":"10.1016\/j.apsb.2016.07.014"},{"issue":"1","key":"3754_CR24","first-page":"3","volume":"2","author":"M Tran","year":"2016","unstructured":"Tran M, Elbarbry F (2016) Influence of diabetes mellitus on pharmacokinetics of drugs. MOJ Bioequiv Availab 2(1):3\u20134","journal-title":"MOJ Bioequiv Availab"},{"key":"3754_CR25","first-page":"561","volume":"15","author":"T Sileshi","year":"2022","unstructured":"Sileshi T, Mekonen G, Makonnen E et al (2022) Effect of genetic variations in drug-metabolizing enzymes and drug transporters on the pharmacokinetics of rifamycins: a systematic review. Pharmgenomics Pers Med 15:561\u2013571","journal-title":"Pharmgenomics Pers Med"},{"issue":"7","key":"3754_CR26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1211\/jpp.62.07.0009","volume":"62","author":"Y Hasegawa","year":"2010","unstructured":"Hasegawa Y, Kishimoto S, Shibatani N et al (2010) Effects of insulin on CYP3A activity and nicardipine disposition in streptozotocin-induced diabetic rats. J Pharm Pharmacol 62(7):883\u20139","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"3754_CR27","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s40200-020-00616-y","volume":"19","author":"G Kuzgun","year":"2020","unstructured":"Kuzgun G, Ba\u015faran R, Ar\u0131o\u011flu \u0130nan E et al (2020) Effects of insulin treatment on hepatic CYP1A1 and CYP2E1 activities and lipid peroxidation levels in streptozotocin-induced diabetic rats. J Diabetes Metab Disord 19(2):1157\u20131164","journal-title":"J Diabetes Metab Disord"},{"issue":"3","key":"3754_CR28","first-page":"474","volume":"47","author":"I De Waziers","year":"1995","unstructured":"De Waziers I, Garlatti M, Bouguet J et al (1995) Insulin down-regulates cytochrome P450 2B and 2E expression at the post-transcriptional level in the rat hepatoma cell line. Mol Pharmacol 47(3):474\u20139","journal-title":"Mol Pharmacol"},{"issue":"8","key":"3754_CR29","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.bcp.2008.01.004","volume":"75","author":"H Liu","year":"2008","unstructured":"Liu H, Liu X, Jia L et al (2008) Insulin therapy restores impaired function and expression of P-glycoprotein in blood-brain barrier of experimental diabetes. Biochem Pharmacol 75(8):1649\u201358","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"3754_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.dmpk.2016.12.003","volume":"32","author":"T Kobayashi","year":"2017","unstructured":"Kobayashi T, Koizumi T, Kobayashi M et al (2017) Insulin stimulates transport of organic anion compounds mediated by organic anion transporting polypeptide 2B1 in the human intestinal cell line Caco-2. Drug Metab Pharmacokinet 32(2):157\u2013163","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"3754_CR31","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/ajm.ajm_53_20","volume":"10","author":"MZ Banday","year":"2020","unstructured":"Banday MZ, Sameer AS, Nissar S (2020) Pathophysiology of diabetes: an overview. Avicenna J Med 10(4):174\u2013188","journal-title":"Avicenna J Med"},{"issue":"14","key":"3754_CR32","doi-asserted-by":"publisher","first-page":"1116226","DOI":"10.3389\/fphar.2023.1116226","volume":"26","author":"R Kim","year":"2023","unstructured":"Kim R, Jayanti RP, Lee H et al (2023) Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on clearance. Front Pharmacol 26(14):1116226","journal-title":"Front Pharmacol"},{"issue":"11","key":"3754_CR33","doi-asserted-by":"publisher","first-page":"19339","DOI":"10.1002\/jcp.28644","volume":"234","author":"H Mashayekhi-Sardoo","year":"2019","unstructured":"Mashayekhi-Sardoo H, Mohammadpour AH, Nomani H et al (2019) The effect of diabetes mellitus on pharmacokinetics, pharmacodynamics and adverse drug reactions of anticancer drugs. J Cell Physiol 234(11):19339\u201319351","journal-title":"J Cell Physiol"},{"issue":"7","key":"3754_CR34","doi-asserted-by":"publisher","first-page":"e00641","DOI":"10.1128\/AAC.00641-18","volume":"62","author":"WA Alghamdi","year":"2018","unstructured":"Alghamdi WA, Al-Shaer MH, Peloquin CA (2018) Protein binding of first-line antituberculosis drugs. Antimicrob Agents Chemother 62(7):e00641-18","journal-title":"Antimicrob Agents Chemother"},{"key":"3754_CR35","doi-asserted-by":"publisher","first-page":"115281","DOI":"10.1016\/j.biopha.2023.115281","volume":"166","author":"J Gouju","year":"2023","unstructured":"Gouju J, Legeay S (2023) Pharmacokinetics of obese adults: not only an increase in weight. Biomed Pharmacother 166:115281","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"3754_CR36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/01.RES.81.3.363","volume":"81","author":"A Hempel","year":"1997","unstructured":"Hempel A, Maasch C, Heintze U et al (1997) High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ Res 81(3):363\u201371","journal-title":"Circ Res"},{"key":"3754_CR37","doi-asserted-by":"publisher","first-page":"100368","DOI":"10.1016\/j.jctube.2023.100368","volume":"31","author":"HT Adane","year":"2023","unstructured":"Adane HT, Howe RC, Wassie L et al (2023) Diabetes mellitus is associated with an increased risk of unsuccessful treatment outcomes among drug-susceptible tuberculosis patients in Ethiopia: a prospective health facility-based study. J Clin Tuberc Other Mycobact Dis 31:100368","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"1","key":"3754_CR38","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1186\/s12879-020-05473-x","volume":"20","author":"A Mily","year":"2020","unstructured":"Mily A, Sarker P, Taznin I et al (2020) Slow radiological improvement and persistent low-grade inflammation after chemotherapy in tuberculosis patients with type 2 diabetes. BMC Infect Dis 20(1):933","journal-title":"BMC Infect Dis"},{"issue":"7273935","key":"3754_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/7273935","volume":"2016","author":"AN Siddiqui","year":"2016","unstructured":"Siddiqui AN, Khayyam KU, Sharma M et al (2016) Effect of diabetes mellitus on tuberculosis treatment outcome and adverse reactions in patients receiving directly observed treatment strategy in India: a prospective study. Biomed Res Int 2016(7273935):1\u201311","journal-title":"Biomed Res Int"},{"issue":"1","key":"3754_CR40","doi-asserted-by":"publisher","first-page":"010502","DOI":"10.11613\/BM.2021.010502","volume":"31","author":"CC Serdar","year":"2021","unstructured":"Serdar CC, Cihan M, Y\u00fccel D et al (2021) Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies. Biochem Med (Zagreb) 31(1):010502","journal-title":"Biochem Med (Zagreb)"},{"key":"3754_CR41","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/978-1-62703-050-2_16","volume":"929","author":"J Gabrielsson","year":"2012","unstructured":"Gabrielsson J, Weiner D (2012) Non-compartmental analysis. Methods Mol Biol 929:377\u201389","journal-title":"Methods Mol Biol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03754-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03754-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03754-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T13:03:17Z","timestamp":1731416597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03754-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3754"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03754-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4735991\/v1","asserted-by":"object"}]},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,17]]},"assertion":[{"value":"13 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}